Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.5.0.2
Basis of Presentation and Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended
Apr. 08, 2015
USD ($)
Mar. 09, 2015
USD ($)
Jun. 30, 2016
USD ($)
shares
Jun. 30, 2015
USD ($)
shares
Jun. 30, 2016
USD ($)
Breathlyzers
shares
Jun. 30, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
Allowance for doubtful accounts receivable     $ 1,010,196   $ 1,010,196   $ 864,000
Allowances charged for doubtful accounts          
Concentration risk percentage         10.00%    
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture $ 64,091 $ 64,675          
Percentage of ownership in Hainan Savy Akers Biosciences, Ltd. joint venture     19.90%   19.90%    
Deferred revenue     $ 115,685 $ 291,868 $ 215,653 291,868  
Shipping, handling and transportation costs     14,387 13,836 30,432 32,778  
Cost of net revenue     47,018 22,716 68,732 67,406  
Net Loss Attributable to Common Stockholders     1,008,932 $ 2,086,229 2,517,861 $ 3,408,028  
Accrued rebates     $ 204,637   $ 204,637   223,542
Options [Member]              
Anti-dilutive securities excluded from computation of earnings per share | shares     220,500 175,000 18,333 175,000  
Trade Receivable [Member]              
Concentration risk percentage         82.00%    
Concentration risk, number of customer | Breathlyzers         3    
Percentage of customer accounted for trade receivables         31.00%    
Fulton Bank of New Jersey [Member]              
Cash     $ 360,856   $ 360,856   369,525
Bank of America [Member]              
Cash     14,635   14,635   28,494
PayPal [Member]              
Cash     4,040   $ 4,040   $ 4,040
Minimum [Member]              
Normal credit terms extended to customers         30 days    
Maximum [Member]              
Normal credit terms extended to customers         90 days    
Cash, FDIC insured amount     $ 250,000   $ 250,000    
Maximum [Member] | Patents [Member]              
Finite-lived intangible asset, useful life         17 years